Miyazaki J - Search Results

1

Risk factors for chronic kidney disease after chemotherapy for testicular cancer.

Inai H, Kawai K, Ikeda A, Ando S, Kimura T, Oikawa T, Onozawa M, Miyazaki J, Uchida K, Nishiyama H. Inai H, et al. Among authors: miyazaki j. Int J Urol. 2013 Jul;20(7):716-22. doi: 10.1111/iju.12017. Epub 2012 Nov 27. Int J Urol. 2013. PMID: 23186076

2

High-dose chemotherapy with peripheral blood stem cell transplantation for advanced testicular cancer.

Miyazaki J, Miyanaga N, Kawai K, Shimazui T, Takeshima H, Akaza H. Miyazaki J, et al. Int J Urol. 2000 Jul;7(7):258-62. doi: 10.1046/j.1442-2042.2000.00187.x. Int J Urol. 2000. PMID: 10910228 Free article. Clinical Trial.

3

Paclitaxel, ifosfamide and cisplatin regimen is feasible for Japanese patients with advanced germ cell cancer.

Kawai K, Miyazaki J, Tsukamoto S, Hinotsu S, Hattori K, Shimazui T, Akaza H. Kawai K, et al. Among authors: miyazaki j. Jpn J Clin Oncol. 2003 Mar;33(3):127-31. doi: 10.1093/jjco/hyg029. Jpn J Clin Oncol. 2003. PMID: 12672789 Clinical Trial.

4

[Prevention and management of nephrotoxicity from anti-cancer agents].

Miyazaki J, Kawai K. Miyazaki J, et al. Nihon Rinsho. 2003 Jun;61(6):973-7. Nihon Rinsho. 2003. PMID: 12806945 Review. Japanese.

5

The limited efficacy of methotrexate, actinomycin D and cisplatin (MAP) for patients with advanced testicular cancer.

Miyazaki J, Kawai K, Hayashi H, Onozawa M, Tsukamoto S, Miyanaga N, Hinotsu S, Shimazui T, Akaza H. Miyazaki J, et al. Jpn J Clin Oncol. 2003 Aug;33(8):391-5. doi: 10.1093/jjco/hyg074. Jpn J Clin Oncol. 2003. PMID: 14523058 Review.

6

[Renal cell carcinoma with bilateral adrenal and small intestinal metastases: a case report].

Ando S, Fukuhara Y, Miyazaki J, Hattori K, Tsukamoto S, Hinotsu S, Shimazui T, Akaza H. Ando S, et al. Among authors: miyazaki j. Nihon Hinyokika Gakkai Zasshi. 2006 Jan;97(1):64-7. doi: 10.5980/jpnjurol1989.97.64. Nihon Hinyokika Gakkai Zasshi. 2006. PMID: 16485557 Free article. Review. Japanese.

7

Uroepithelial cells can directly respond to Mycobacterium bovis bacillus Calmette-Guérin through Toll-like receptor signalling.

Miyazaki J, Kawai K, Oikawa T, Johraku A, Hattori K, Shimazui T, Akaza H. Miyazaki J, et al. BJU Int. 2006 Apr;97(4):860-4. doi: 10.1111/j.1464-410X.2006.06026.x. BJU Int. 2006. PMID: 16536788

8

Prediction of in vitro response to interferon-alpha in renal cell carcinoma cell lines.

Shimazui T, Ami Y, Yoshikawa K, Uchida K, Kojima T, Oikawa T, Nakamura K, Honda N, Hinotsu S, Miyazaki J, Kunita N, Akaza H. Shimazui T, et al. Among authors: miyazaki j. Cancer Sci. 2007 Apr;98(4):529-34. doi: 10.1111/j.1349-7006.2007.00421.x. Epub 2007 Jan 31. Cancer Sci. 2007. PMID: 17284252 Free PMC article.

9

Immunoprotection against murine bladder carcinoma by octaarginine-modified liposomes incorporating cell wall of Mycobacterium bovis bacillus Calmette-Guérin.

Joraku A, Homhuan A, Kawai K, Yamamoto T, Miyazaki J, Kogure K, Yano I, Harashima H, Akaza H. Joraku A, et al. Among authors: miyazaki j. BJU Int. 2009 Mar;103(5):686-93. doi: 10.1111/j.1464-410X.2008.08235.x. Epub 2008 Nov 25. BJU Int. 2009. PMID: 19040525

10

The liposome-incorporating cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guéin can directly enhance the susceptibility of cancer cells to lymphokine-activated killer cells through up-regulation of natural-killer group 2, member D ligands.

Miyazaki J, Kawai K, Kojima T, Oikawa T, Joraku A, Shimazui T, Nakaya A, Yano I, Nakamura T, Harashima H, Akaza H. Miyazaki J, et al. BJU Int. 2011 Nov;108(9):1520-6. doi: 10.1111/j.1464-410X.2010.10056.x. Epub 2011 Feb 11. BJU Int. 2011. PMID: 21314815

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

805 results

Search Page

Filters